All In Biotech

Drug Trial Radar · NCT01402492

Cocaine Use Reduction With Buprenorphine

Cocaine Use Reduction With Buprenorphine (CURB)

Last checked: Nov 20, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

302

Actual

Start

Sep 2011

Primary completion

Jan 2013

Study completion Mar 2013

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC
First posted
Jul 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence.

Conditions

  • Cocaine Dependence

Interventions

  • Buprenorphine + NaltrexoneDrug

    Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.

  • Placebo + NaltrexoneDrug

    Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cocaine Use Days as Measured by Self-report, Corroborated by Thrice-weekly Urine Drug ScreensTime frame: final 30 days of Treatment Phase, study days 25-54

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Integrated Substance Abuse Programs (ISAP)

    Los Angeles, California

  • Bay Area Addiction Research and Treatment (BAART)

    San Francisco, California

  • Addiction Research and Treatment Services (ARTS)

    Denver, Colorado

  • Howard University Hospital

    Washington D.C., District of Columbia

  • Atlanta VA Medical Center

    Atlanta, Georgia

  • Bellevue Hospital Center

    New York, New York

  • Albert Einstein College of Medicine - Division of Substance Abuse

    The Bronx, New York

  • Maryhaven

    Columbus, Ohio

  • CODA, Inc.

    Portland, Oregon

  • South Texas Veterans Health Care System

    San Antonio, Texas

  • Recovery Centers of King County (RCKC)

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.